ArticleMedical oncology (Northwood, London, England)2015
Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 45 citations in OpenAlex.
- The YY1-KIF15-PRDX1 axis promotes gastric cancer progression by inducing mitochondrial ROS imbalance.Oncogene · 2026Article
- Peroxisomal activity drives aggressive bladder cancer phenotypes and reveals erythorbic acid as a potential therapeutic modulator.Frontiers in oncology · 2026Article
- Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells.World journal of gastroenterology · 2025Article
- Unveiling ferroptosis genes and inhibitors in diabetic retinopathy through single-cell analysis and docking simulations.Biochemistry and biophysics reports · 2025Article
- Primary cilia-associated signalling in squamous cell carcinoma of head and neck region.Frontiers in oncology · 2024Review
- Expression And Prognostic Role of PRDX1 In Gastrointestinal Cancers.Journal of Cancer · 2023Article
- Effects of Antioxidant Gene Overexpression on Stress Resistance and Malignization In Vitro and In Vivo: A Review.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1.Journal of gastrointestinal oncology · 2022Article
- Proteomic Analysis of Endometrial Cancer Tissues from Patients with Type 2 Diabetes Mellitus.Life (Basel, Switzerland) · 2022Article
- Membrane Bound Peroxiredoxin-1 Serves as a Biomarker forAntioxidants & redox signaling · 2022Article
- Comparative proteomics analysis ofFrontiers in cellular and infection microbiology · 2022Article
- Comparative Study of Protective Action of Exogenous 2-Cys Peroxiredoxins (Prx1 and Prx2) Under Renal Ischemia-Reperfusion Injury.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- Characterization of exosomes in peritoneal fluid of endometriosis patients.Fertility and sterility · 2020Article
- ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.Oxidative medicine and cellular longevity · 2020Review
- Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.Journal of virology · 2019Article
- MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation.World journal of gastroenterology · 2019Article
- The Prognosis Of Peroxiredoxin Family In Breast Cancer.Cancer management and research · 2019Article
- The prognostic values of the peroxiredoxins family in ovarian cancer.Bioscience reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biological function of Peroxiredoxin 1 (Prdx1) in cancer is still ambiguous, and its mechanism has not been elucidated so far. Previous studies have shown that Prdx1 functions as tumor suppressor in several types of cancers, but other studies have indicated that it is overexpressed in some types of human cancers, and inhibition of Prdx1 by shRNA contributes to radiosensitivity and chemosensitivity. In this study, a suppression subtractive hybridization cDNA library between esophageal squamous cell carcinoma (ESCC) cell line EC9706 and noncancerous esophageal epithelial cell line Het-1A was constructed, and 11 tumorigenesis-associated genes including Prdx1 were isolated. In addition, we further confirmed that Prdx1 was overexpressed in ESCC cells at the level of protein compared with Het-1A (P < 0.05). Inhibition of Prdx1 by shRNA lentivirus decreased cell proliferation and invasion, and induced cell apoptosis, but did not affect cell cycle distribution of EC9706 cells (P > 0.05). Importantly, the total proteins of mTOR and p70S6K, as well as the activity of mTOR/p70S6K signaling pathway, were decreased in Prdx1-depletion EC9706 cells. Furthermore, the activity of mTOR/p70S6K signaling pathway was increased in Prdx1-overexpressing Het-1A cells. These findings mentioned above demonstrate that Prdx1 may be involved in tumorigenesis through regulation of mTOR/p70S6K pathway in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.